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bstract
bjective:  The effect of casein glycomacropeptide (CGMP) on the expression of NF-B subunit p65 in human colorectal cancer HT-29 cells
nduced by lipopolysaccharide (LPS) was investigated to explore the therapeutic efficacy of CGMP for human colorectal cancer.
ethods:  HT-29 cells cultured in 96-well plates were stimulated with LPS for 30 min at the concentrations of 0, 0.001, 0.01, 0.1, 1 and 10 g/mL.
fter stimulation, the expression of p65 in HT-29 cells was evaluated by immunofluorescence method. Similarly, HT-29 cells were incubated with
, 0.001, 0.01, 0.1, 1, 10 and 100 g/mL CGMP for 24 h at the optimal LPS concentration. After treatment with CGMP under the incubation with
ptimal LPS concentration for 30 min, the protein expression of p65 was analyzed by Western blotting. The optimum culture time was evaluated
y incubating HT-29 cells with the optimal CGMP concentration for 6, 12, 24, 48 and 72 h.
esults:  NF-B-p65 revealed that the highest protein expression was achieved with 1 g/mL LPS treatment. Meanwhile, CGMP could inhibit
he protein expression of NF-B-p65 in LPS-stimulated HT-29 cells, and the optimal inhibitory effect was observed at a CGMP concentration of
.01 g/mL with 48 h incubation.
onclusion:  CGMP can regulate NF-B signaling pathway through inhibiting the expression of its subunit p65, which is beneficial for the further
mprovement of human colorectal cancer treatment.
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CGMP is a glycopeptide containing sialic acid discovered by
elfour in 1965 [1]. It is a polypeptide fragment of -casein
-CN, a unique sugar composition in CN) in milk. During the
roduction process of cheese, rennet casein can hydrolyze the
he-Met peptide bond of -CN in milk to generate insoluble sub-
-CN (the 1–105 amino acid residual part of the peptide chain)
nd soluble polypeptide (106–169 amino acid residual part of
he peptide chain). Such polypeptide containing a large number
f carbohydrates is called glycomacropeptide. Correspondingly,∗ Corresponding author at: Tianjin Key Laboratory of Food Biotechnology,
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he glycomacropeptide from casein is named as casein glyco-
acropeptide (CGMP). During the past decade, CGMP, as a
ioactive component, has attracted extensive attention due to
ts unique chemical and functional properties. Its most promis-
ng applications are to inhibit hemagglutinin of influenza virus,
nhibit the secretion of gastric juice, promote the proliferation
f Biﬁdobacteria, and modulate the response of immune sys-
ems [2–5]. In recent years, under the continuous support by
he National Natural Science Foundation of China, our research
roup has systematically investigated the effect of CGMP on
he regulation of the intestinal immune system, and the change
f intestinal flora and intestinal inflammatory reactions. Our
nvestigations have confirmed the anti-informatory activity of
GMP, which can improve, alleviate and cure inflammatory
owel diseases (IBD) to some extents [6]. However, the specific
nti-inflammatory activity and corresponding clear mechanisms
f CGMP still need further investigation to explore its effect on
elevant immune molecules and immune signaling pathways,
hich will be beneficial for further elucidating the mechanism
f IBD treatment.
NF-B is discovered by Baltimore from Cancer Research
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iomedical Research of Whitehead Institute at MIT [7] in 1986,
s a transcription factor widely present in mammalian cells.
t can bind to the specific site of a promoter or an enhancer
o promote the transcription and expression of a variety of
enes, which can regulate apoptosis, cell adhesion, cell prolif-
ration, natural and adaptive immune response, inflammation,
tress response and intracellular tissue remodeling processes
8–10]. The ubiquitous distribution of NF-B in the body has
ained more and more attention, and NF-B has become an
mportant treatment target of many diseases [11]. The nuclear
ranslocation of p65 is the signal for NF-B activation, and the
nitiation of physiological and pathological changes of NF-B.
he content of p65 in cells is extremely low, but it can contact
ith DNA extensively due to its high affinity to DNA. There-
ore, p65 is highly efficient and accurate in recognizing target
ites. In addition, nuclear transfer can be achieved through the
issociation of p65 and IB without the requirement of new
rotein synthesis process. Thus it may induce fast gene transcrip-
ion, and is involved in the transcriptional regulation of instant
enes associated with stress defense responses [12]. Further-
ore, CGMP plays an important role in the nuclear translocation
f p65 during NF-B activation or inhibition process. If
GMP inhibits the starting point of a series of cascade reac-
ions, CGMP can subsequently terminate the pathophysiological
rocesses.
.  Materials  and  methods
.1.  Chemicals  and  reagents
HT-29 cells were purchased from Qishi Biotechnology Co.,
td., China. Fetal bovine serum (FBS) was ordered from
ibco, USA. DMEM medium with high glucose was pur-
hased from HyClone Laboratories, Inc., USA. CGMP was
rdered from Tatua Company, New Zealand. LPS was pur-
hased from Sigma–Aldrich, USA. Nuclear and plasma protein
xtraction kits, BCA protein assay kit, 5×  protein sample
uffer, horseradish peroxidase (HRP)-labeled goat anti-rabbit
gG, and fluorescein isothiocyanate (FITC)-labeled goat anti-
abbit IgG were purchased from Beijing Kangwei Century
iotechnology Co., Ltd., China. Rabbit anti-human poly-
lonal antibody p65 and rabbit anti-human LaminA polyclonal
ntibody were purchased from Abcam, USA. ECL chemi-
uminescent substrate hypersensitivity test kit was purchased
rom Millipore, USA. Other reagents were of analytical
rade.
.2.  Human  colon  cancer  HT-29  cells  culture
HT-29 cells were cultured in DMEM medium with high
lucose supplemented with 10% penicillin (100 U/mL) and
treptomycin (100 U/mL). The cells were cultured at CO2 incu-
ators (HERAcell 240i, Thermo Fisher Scientific, USA,) with
◦7 C and 5% CO2. The cell culture medium was changed every
wo days. After cells were seeded in 96-well plates or cell culture
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.3.  Study  design
After the cells grown to sub-confluence stage, serum-free
ynchronization was conducted for 6 h. The experiment was
onducted into two parts.
Part A: eight groups include a control group (N group), a
PS group (L group), and six CGMP groups with different
GMP concentration (C1: 0.001 g/mL, C2: 0.01 g/mL, C3:
.1 g/mL, C4: 1 g/mL, C5: 10 g/mL, and C6: 100 g/mL).
he cells were cultured at 37 ◦C with 5% CO2 for 24 h. Except
or the control group, the cells were incubated with LPS at
7 ◦C with 5% CO2 for 30 min. Cells were then rinsed with
BS buffer 2 times (5 min each time) prior to digestion with
.25% trypsin for 2 min. After the termination of digestion, the
ells were collected and counted after centrifugation at 4 ◦C and
000 rpm/min.
Part B (five groups): the cells were treated with the optimum
GMP dose at 37 ◦C and 5% CO2 for 6, 12, 24, 48 and 72 h and
rocessed similarly as described above.
.4.  Protein  expression  of  p65  evaluated  by
mmunoﬂuorescence
Cells were seeded in 96-well microplates containing DMEM
ulture medium with high glucose supplemented with 10%
BS. After the cell population reached 60%–70% of the well
in logarithmic phase), the serum-free medium was used for
ynchronized culture for 6 h. The experiment was divided into
ix groups including control group (Group B) and five LPS
oncentration groups (L1: 0.001 g/mL; L2: 0.01 g/mL; L3:
.1 g/mL; L4: 1 g/mL; and L5: 10 g/mL). After the LPS
reatment for 30 min, the cells were washed with PBS buffer 3
imes for 5 min each time. Then, the cells were fixed with chilled
% formaldehyde for 10 min, and washed with PBS buffer 3
imes for 5 min each time. The cells were blocked with PBS
uffer containing 0.3% Triton X-100, 2% BSA and 2% goat
erum for 1 h at room temperature. The treated cells were incu-
ated with primary antibody of p65 at 37 ◦C for 1 h, followed
y PBS buffer washing for 3 times (5 min each time). Sequen-
ially, the p65 was probed with Cy3-labeled secondary antibody
t 37 ◦C for 1 h, and then the probed cells were washed with PBS
uffer 3 times (5 min each time). The fluorescence intensity of
he mixture was determined by a fluorescence microplate reader
SpectraMax M5; Molecular Devices, USA) with the excitation
avelength of 488 nm and the emission wavelength of 525 nm.
.5.  Expression  of  p65  protein  in  cells  evaluated  by  Western
lotting
1 mL protein extraction reagent containing phosphatase
nhibitor was added to 107 cells, and the mixture was incu-
ated on ice for 15 min. The supernatant was collected after
entrifugation at 4 ◦C and 12,000 r/min for 20 min. The protein
oncentration was first determined by BCA protein assay before
ample loading. 40 L nuclear protein solution was mixed with
× sample buffer at a volume ratio of 1:4. The protein was
enatured by boiling for 5 min, and cooled down to room








































Fig. 2. Effect of CGMP on the protein expression of p65. (A) Western blot of p65
and LaminA in the control group; (B) densitometry of p65/LaminA. Note: N:
control group; L: LPS group; C1: 0.001 g/mL CGMP group; C2: 0.01 g/mL
CGMP group; C3: 0.1 g/mL CGMP group; C4: 1 g/mL CGMP group; C5:
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emperature. The electrophoresis was conducted at a voltage
f 80 V using 5% polyacrylamide stacking gel and at 100 V
sing 12% separating gel. Upon the completion of electrophore-
is, the protein was transferred to PVDF membrane (Millipore,
SA). The PVDF membrane was blocked in 5% skim milk at
oom temperature for 1 h. Sequentially, the protein on the PVDF
embrane was probed with rabbit anti-human p65 antibody at a
ilution ratio of 1:1000 at room temperature for 2 h. The PVDF
embrane was washed with PBS-T buffer 4 times for 5 min each
ime. After incubating with primary antibody, the PVDF mem-
rane was targeted with peroxidase-labeled goat anti-rabbit IgG
ntibody at a dilution ratio of 1:5000 at room temperature for
 h. Finally, ECL color reaction was conducted for gel imaging
nalysis. The target protein bands and reference protein bands
ere analyzed by Quantity One gel imaging software.
.6.  Statistical  analysis
The experimental data were analyzed using SPSS 17.0 sta-
istical software through variance analysis. The results were
xpressed as mean ±  standard deviation (x¯  ±  s). The significant
ifference was considered at P  < 0.05.
.  Results
.1.  Fluorescence  intensity  changes  of  p65  in  HT-29  cells
nder the  stimulation  of  LPS
The green fluorescence of FITC was excited at the wave-
ength of 488 nm, and relative fluorescence units (RFUs) were
etected using a multifunctional plate reader with dual-grating
ull wavelength scanning. The fluorescence intensity of p65 in
T-29 cells from each group is shown in Fig. 1. Compared with
he control group, the fluorescence intensity of p65 revealed an
nitial increase and a final decrease with the increase of LPS
osage. Although the fluorescence intensity of p65 exhibited a
nal reduction, the fluorescence intensity of p65 in LPS groups
as higher than that in the control group. Among the LPS groups,
he fluorescence intensity of p65 from L2 group (0.01 g/mL),
3 group (0.1 g/mL) and L4 group (1 g/mL) revealed a very
ignificant increase (P  < 0.01), as well as a significant increase
n L5 group (10 g/mL) (P  < 0.05).
ig. 1. Effect of LPS on RFUs of p65. Note: B: blank control group; L1:
.001 g/mL LPS group; L2: 0.01 g/mL LPS group; L3: 0.1 g/mL LPS group;
4: 1 g/mL LPS group; and L5: 10 g/mL LPS group; *difference from the















oontrol group (P < 0.05); **significant difference (P < 0.01); +difference from
PS group (P < 0.05); ++significant difference (P < 0.01).
.2.  Effect  of CGMP  dosages  in  protein  expression  of p65
Effect of CGMP on the protein expression of p65 is shown
n Fig. 2. Compared with the control group, the content of
65 protein in HT-29 cells from LPS groups revealed a sig-
ificant enhancement (P  < 0.05). On the other hand, the protein
xpression of p65 in CGMP groups exhibited an initial decrease
nd a final increase. Among these CGMP groups, the protein
xpression of p65 in HT-29 cells from C2 revealed the most
bvious inhibition (P  < 0.05). Compared with the LPS group,
1, C2 andC3 revealed a significant reduction in expression of
65 protein under the stimulation of LPS (P  < 0.05), which was
bviously lower than that in the control group. Although the pro-
ein expression of p65 in C4, C5 and C6 revealed a reduction, it
as still higher than that in the control group without significant
ifference.
.3.  Effect  of treatment  duration  on  the  protein  expression
f p65
The effect of treatment duration on the expression of p65
ith the optimal CGMP dose is shown in Fig. 3. The expression
f p65 revealed an increase as the extension of treatment dura-
ion and reached the maximum after 12 h treatment; however,
he expression of p65 exhibited a decreasing trend after 12 h,
nd reached the lowest level after the treatment of 48 h. Cells
reated with CGMP for 12 h showed the highest expression of
65, which was very significantly different compared with other
our groups (P  < 0.01). In contrast, cells treated with CGMP
or 48 h showed the lowest expression level of p65, which was
ery significantly different compared with the that in the cells
reated for 6, 12 and 72 h (P  < 0.01), but it showed no significant
ifference compared with that in the cells treated for 24 h. As
he extension of CGMP treatment time, 72 h treatment revealed
he increase in the expression of p65 again, which exhibited an
bvious enhancement when compared with the treatment for 24
54 J. Gong et al. / Food Science and Hu
Fig. 3. Effect of treatment duration on p65 expression in the presence of
CGMP. (A) Western blot of p65 and LaminA in control group; (B) densitome-
try of p65/LaminA. Note: *Difference from 6 h group (P < 0.05); **significant
difference (P < 0.01); #difference from 12 h group (P < 0.05); ##significant differ-
ence (P < 0.01); +difference from 24 h group (P < 0.05); ++significant difference





















































































In summary, CGMP at low dose levels can significantlyP < 0.01); difference from 72 h group (P < 0.05); significant difference
P < 0.01).
nd 48 h (P  < 0.05), but was still significantly lower than the
xpression of p65 in cells with12 h CGMP treatment (P  < 0.01).
.  Discussion
CGMP, as a novel biologically active functional factor, has
een confirmed to exert many biological functions which make it
articularly suitable for functional health products. The in-depth
xploration of the functional activity of CGMP will not only
mprove the utilization of milk resources, but also further explore
ts more potential value. Currently, health-promoting roles of
GMP have been discussed from different respects [13,14];
owever, its mechanisms of the action are not discussed and
xplored. Foods can not only provide the nutrition and energy for
ife events, but also can adjust cytokine network through regulat-
ng immune network, message-passing network and metabolic
etwork, thus regulating the health of the body and life events
orrespondingly [15,16]. The activity of NF-B is strictly regu-
ated by multiple factors due to its role as a transcription factor.
he cells can only survive and play their physiological functions
y maintaining the homeostasis of NF-B activity. Previous
tudies have demonstrated that persistent activation of NF-B
xists in a number of disease statuses, while the reduced activ-
ty of NF-B is observed in some other autoimmune diseases.
he disturbed homeostasis, i.e., the excessive activation or inhi-
ition of NF-B, will cause physiological disorders or lead to
iseases such as rheumatoid arthritis, atherosclerosis, multiple
clerosis and asthma inflammation, as well as cancers including
rostate cancer, glioma and lymphoma [8–10]. Thus it is impor-
ant to maintain the balance of NF-B activity. In most of the
ells at the resting state, the dimer subunit of NF-B in cell cyto-
lasm can bind with its inhibitor (inhibitor of NF-B, IB) to
orm a trimeric complex of p65–p50–IB. Upon the stimulation
i
w
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y pathogens, stress, cytokines, oxygen radicals, oncoproteins
nd ultraviolet light, IBs were degraded by phosphorylation
r ubiquitination. The inhibition of the p65–p50 dimer by IBs
ill be released quickly and nuclear translocation will occur,
eading to initiate or promote the transcription of certain genes
17]. Requena et al. [18] have demonstrated that CGMP at
igh concentrations may activate the NF-B signaling pathway,
nd that bovine casein glycomacropeptide (BGMP) in the gut
ay exert an anti-inflammatory effect. Therefore, to explore the
echanisms of physiological functions, we have investigated
he protein expression levels of p65 in LPS-stimulated HT-29
ells through CGMP intervention at low concentrations.
In the present study, the activation of NF-B signaling
athway in the presence of LPS was determined by immuno-
uorescence, which revealed that the expression of p65 was
ncreased with LPS in a dose-dependent manner. However, the
uorescence intensity of p65 revealed an initial increase and a
nal decrease with the increase of LPS doses, with the most
ffective dose at 1 g/mL. LPS may enter the intestinal tract
uring infection, thereby activating monocytes, macrophages
nd endothelial cells to synthesize and release various cytokines
nd inflammatory mediators. This thus leads to increased vas-
ular permeability, fluid exudation and lymphocyte migration to
nflammation sites, a defensive reaction of the body to remove
athogens and recover the body. Excessive defensive reactions
an cause hardly controlled inflammatory cascades or serious
isorders in immune functions [19]. Therefore, LPS was applied
o activate NF-B signaling pathway in our study. It can be seen
rom the Western blotting results that CGMP at the six con-
entrations could inhibit the expression of p65 in HT-29 cells
fter LPS stimulation, especially the low concentrations (0.001,
.01 and 0.1 g/mL). Although high concentrations (1, 10 and
00 g/mL) of CGMP had inhibitory effect on the expression of
65, it was still higher than that in the control group. Requena
t al. [18] have employed monocytic leukemia cells (THP-1) as
 model. The cells are cultured in complete medium containing
GMP at a gradient concentration of 0.01–10 mg/mL for 24 h.
B detection has confirmed the phosphorylation of IB32 at
he serine sites and protein expression of p50 and p65 at different
ime points. Results have revealed that BGMP can activate NF-
B. One hour after addition of BGMP, the highest expression
f p-IB, p50 and p65 was observed, which is contrary to our
xperimental results. Therefore, the correlation between CGMP
ntake and its immunomodulatory effects needs to be further
xplored. During the investigation of optimum CGMP treatment
uration, the expression of p65 revealed an initial enhancement
nd a final reduction with the extension of treatment duration,
ith the highest expression level occurring after treatment for
2 h and the lowest expression level after treatment for 48 h.
herefore, longer treatment duration does not mean higher sup-
ression efficiency on p65. Various cytokines are released with
he growth of cells, which may interact with CGMP to reduce
ts suppression effect on p65.nhibit the expression of p65 in the NF-B signaling pathway,
hich may serve as a target for treatments of colorectal can-
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he application of CGMP in the field of functional health prod-
cts as well as a scientific reference for nutrition therapies of
olorectal cancer. However, the interactions of CGMP and other
roteins such as 26S, ubiquitin proteasome and NEMO in the
F-B signaling pathway need to be further explored to provide
 more complete theoretical basis to illustrate the mechanisms
f its anti-inflammatory and anti-cancer activity.
.  Conclusion
Based on the fluorescence intensity changes of p65 in this
tudy, LPS at concentration of 0.01, 0.1 and 10 g/mL can
ignificantly activate NF-B signaling pathway (P  < 0.05) and
timulate the expression of p65. The maximum express was
chieved at a LPS concentration of 1 g/mL and treatment
uration of 30 min (P  < 0.01). CGMP with the tested doses
an all inhibit the expression of p65 in LPS-stimulated HT-29
ells, with the optimum concentration of 0.01 g/mL and treat-
ent duration of 48 h (P  < 0.05). Therefore, CGMP can inhibit
he activation of NF-B signaling pathway by inhibiting the
xpression of p65, which provides a theoretical basis for the
mprovement and treatment of colorectal cancer triggered by
BD through the regulation of NF-B signaling pathway.
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